Kimberly Garcia
Psychiatric/Mental Health · Allentown, PANPI 1245441765
Payments from drug & device makers
Across 816 payments — averaging $702.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$417K
- Teva Pharmaceuticals USA, Inc.$106K
- AbbVie$36K
- E.r. Squibb & Sons, L.L.C.$11K
- Alkermes, Inc.$1K
- Neurocrine Biosciences, Inc.$597
- plus $1K from 8 others
What the payments were for
- Consulting fees$35,7356%
- Speaking & faculty fees$438,01176%
- Travel & lodging$84,38115%
- Food & beverage$14,5323%
- Education$2400%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 395 | $417,499 |
| Teva Pharmaceuticals USA, Inc. | 176 | $106,013 |
| AbbVie(2 entities) | 105 | $35,506 |
| E.r. Squibb & Sons, L.L.C. | 30 | $10,839 |
| Alkermes, Inc. | 47 | $1,366 |
| Neurocrine Biosciences, Inc. | 9 | $597 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 15 | $311 |
| Vanda Pharmaceuticals Inc. | 13 | $285 |
| Otsuka America Pharmaceutical, Inc. | 11 | $208 |
| Lundbeck LLC | 6 | $131 |
| Axsome Therapeutics, Inc. | 2 | $53 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $42 |
| Sunovion Pharmaceuticals Inc. | 3 | $35 |
| Eisai Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INVEGA SUSTENNA$405,453
- INVEGA TRINZA$401,606
- UZEDY$93,347
- VRAYLAR$33,969
- Austedo XR$9,825
- INVEGA$8,375
- LYBALVI$1,600
- ARISTADA$499
- INGREZZA$488
- ARISTADA INITIO$125
- SPRAVATO$123
How this compares
$572,900 in reported general payments places this provider in the 95th percentile of 1,041 psychiatric/mental health providers in Pennsylvania.
See all psychiatric/mental health providers in Pennsylvania →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 189 | $614,854 |
| Tasimelteon | 12 | $210,208 |
| Invega HafyeraPaliperidone Palmitate | 11 | $200,907 |
| Abilify MaintenaAripiprazole | 55 | $151,807 |
| Invega TrinzaPaliperidone Palmitate | 16 | $128,537 |
| IngrezzaValbenazine Tosylate | 14 | $118,063 |
| VraylarCariprazine Hcl | 68 | $102,671 |
| AristadaAripiprazole Lauroxil | 17 | $46,600 |
| RexultiBrexpiprazole | 24 | $33,639 |
| CaplytaLumateperone Tosylate | 13 | $20,339 |
| Divalproex Sodium ErDivalproex Sodium | 244 | $18,244 |
| Aripiprazole | 262 | $16,445 |
| Chlorpromazine Hcl | 30 | $13,089 |
| Quetiapine Fumarate | 663 | $11,621 |
| Lurasidone Hcl | 40 | $10,586 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna, Invega Trinza | $417,499 | $743,391205 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti | $208 | $185,44679 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $597 | $118,06314 claims |
| AbbVieVraylar | $35,506 | $102,67168 claims |
| Alkermes, Inc.Aristada | $1,366 | $46,60017 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $311 | $20,33913 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $42 | $9,66919 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,041 psychiatric/mental health providers in Pennsylvania.
Other psychiatric/mental health in Allentown
- Cortney SmithWashington$227K
- Britney KeplerPittsburgh$158K
- Kirstyn KamegBethel Park$136K
- Anna DipietroDowningtown$131K
- Deena MasciocchiLanghorne$71K
- Joseph GagnonChesterbrook$64K
- Michelle CohenWashington$62K
- Sharon KatzJenkintown$51K
- Jennifer BowmanCanonsburg$48K
- Dylan KilmerGreenfield Township$44K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.